POCI: Precision Optics Corporation, Inc. Stock

by  •  • Comments Off on POCI: Precision Optics Corporation, Inc. Stock

SIC 3845 – Electromedical and Electrotherapeutic Apparatus

Valuation
Market Cap ($M) 33.98
Enterprise Value ($M) 35.43
Book Value ($M) 11.32
Book Value / Share 1.86
Price / Book 3.00
NCAV ($M) 1.45
NCAV / Share 0.24
Price / NCAV 23.40

Profitability (mra)
Return on Invested Capital (ROIC) -0.12
Return on Assets (ROA) -0.09
Return on Equity (ROE) -0.18

Liquidity (mrq)
Quick Ratio 1.10
Current Ratio 1.82

Balance Sheet (mrq) ($M)
Current Assets 7.83
Assets 17.70
Liabilities 6.38
Debt n/a
Equity n/a

Income Statement (mra) ($M)
Revenue 0.00
Operating Income 0.00
Net Income 0.00
Earnings Per Share Basic And Diluted n/a
Earnings Per Share Diluted n/a
Earnings Per Share Basic n/a

Cash Flow Statement (mra) ($M)
Cash From Operations 0.00
Cash from Investing 0.00
Cash from Financing 0.00

(click for more detail)

File Date Form Activist 13D/G Investors Ownership
(%)		 Change
(%)
2023-04-17 13D Anania Peter V. 4.10 0.00

Top 13F Investors Shares
(1000)		 Change
(%)		 Value
($1000)		 Change
(%)

(click for more detail)

Date Insider Trades Code Shares Value

(click for more detail)

File Date Form SEC Filings
2024-02-28 10-K/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A (Amendment No. 1)
2024-02-14 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31, 2023 ☐ TRANSITION REPORT PURSUANT
2023-11-14 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 ☐ TRANSITION REPORT PURSUANT
2023-09-28 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K
2023-05-15 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 ☐ TRANSITION REPORT PURSUANT TO

(click for more detail)
Short Volume
Market Date Short Volume Total Volume Short Volume Ratio
2024-04-26 2,716 346 784.97
2024-04-25 1,003 375 267.47
2024-04-24 700 1,377 50.84
2024-04-23 1,366 2,240 60.98

(click for more detail)

Similar Companies
PDEX – Pro-Dex, Inc. PLSE – Pulse Biosciences, Inc.
POAI – Predictive Oncology Inc. PROF – Profound Medical Corp.
PSTV – Plus Therapeutics, Inc.


Financial data and stock pages provided by
Fintel.io